C12N 7/00
Viruses
Official title: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
C12N7/00 (Viruses) appears on 8,547 US grants and 12,749 published applications in this corpus.
Search patents in C12N- Granted patents
- 8,547
- Published applications
- 12,749
- Assignees
- 3,751
- Inventors
- 18,295
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 10 | 0 |
| 1977 | 9 | 0 |
| 1978 | 12 | 0 |
| 1979 | 8 | 0 |
| 1980 | 10 | 0 |
| 1981 | 7 | 0 |
| 1982 | 8 | 0 |
| 1983 | 9 | 0 |
| 1984 | 8 | 0 |
| 1985 | 17 | 0 |
| 1986 | 10 | 0 |
| 1987 | 15 | 0 |
| 1988 | 11 | 0 |
| 1989 | 11 | 0 |
| 1990 | 7 | 0 |
| 1991 | 14 | 0 |
| 1992 | 21 | 0 |
| 1993 | 26 | 0 |
| 1994 | 28 | 0 |
| 1995 | 28 | 0 |
| 1996 | 48 | 0 |
| 1997 | 88 | 0 |
| 1998 | 112 | 0 |
| 1999 | 116 | 0 |
| 2000 | 137 | 0 |
| 2001 | 154 | 45 |
| 2002 | 135 | 186 |
| 2003 | 155 | 323 |
| 2004 | 134 | 274 |
| 2005 | 101 | 299 |
| 2006 | 145 | 302 |
| 2007 | 169 | 290 |
| 2008 | 158 | 300 |
| 2009 | 175 | 374 |
| 2010 | 204 | 466 |
| 2011 | 187 | 417 |
| 2012 | 213 | 396 |
| 2013 | 223 | 410 |
| 2014 | 330 | 493 |
| 2015 | 344 | 667 |
| 2016 | 444 | 862 |
| 2017 | 476 | 783 |
| 2018 | 569 | 638 |
| 2019 | 581 | 720 |
| 2020 | 528 | 805 |
| 2021 | 462 | 760 |
| 2022 | 431 | 679 |
| 2023 | 389 | 539 |
| 2024 | 426 | 725 |
| 2025 | 411 | 591 |
| 2026 | 233 | 405 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Coating composition comprising bacteriophage and antibacterial film formed by using same6 Oct 2026US 12,751,458 B2Kookmin University Industry Academy Cooperation Foundation
- Bacteriophage compositions for treating Staphylococcus infection6 Oct 2026US 12,751,983 B2Armata Pharmaceuticals, Inc.
- Mutant influenza B/Victoria lineage virus hemagglutinin proteins6 Oct 2026US 12,752,001 B2ModernaTX, Inc.
- Antiviral structurally-stabilized Ebolavirus peptides and uses thereof6 Oct 2026US 12,753,208 B2Dana-Farber Cancer Institute, Inc.
- Orthogonal ubiquitin transfer as a method to identify cellular substrates of E3 ubiquitin ligases6 Oct 2026US 12,753,402 B2Georgia State University Research Foundation, Inc.
- Treating a type i interferon upregulation or aberrant il-33 upregulation disease or condition with polyomavirus8 Oct 2026US 2026/0306609 A1The General Hospital Corporation
- Systems and Methods for Delivery of Viral Antigens8 Oct 2026US 2026/0306610 A1Veergen Inc.
- Differential coating of microprojections and microneedles on arrays8 Oct 2026US 2026/0306611 A1Vaxxas Pty Limited
- Spike Protein Based Genetic Vaccines8 Oct 2026US 2026/0306616 A1University of Maryland, Baltimore
- Tumor neoantigen vaccine system specifically marking heterologous protein, and use thereof8 Oct 2026US 2026/0306620 A1China Pharmaceutical University
Most cited
By later US patents
- Directed evolution of novel binding proteins2,450US 5,223,409 AProtein Engineering Corporation · 1993
- Immunizing compositions comprising nucleic acids encoding the HIV-1 matrix protein myristate binding site1,449US 7,718,180 B22010
- Plant expression constructs1,417US 6,660,911 B2Monsanto Technology LLC · 2003
- Chimeric figwort mosaic virus-elongation factor 1 α promoters and methods of using them1,389US 6,949,696 B2Monsanto Technology LLC · 2005
- Glyphosate resistant plants using hybrid promoter constructs1,380US 7,141,722 B2Monsanto Technology LLC · 2006